Anti-ErbB2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1

  • 1.00 Dollar US$
  • Published date: March 6, 2018
    • Shirley, New York, United States
Anti-ErbB2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1
Anti-ErbB2 scFv h(CD4-FcεRIγ) CARNK, pCDCAR1

https://www.creative-biolabs.com/car-t/pcdcar1-erbb2-h-4γ-nk-281.htm The vector of anti-ErbB2 (HER2) chimeric antigen receptor(CAR) is constructed for the engineering of NK cell to target human ErbB2. The NK cell is genetically modified through transduction with a lentiviral vector expressing scFv of anti-ErbB2 antibody linked to CD4 transmembrane domain and FcεRIγ signaling domains. And the vector product was designed for the treatment of breast carcinomas, ovarian carcinoma .

Result 0 votes
Jerry Carter
1 votes

Useful information

  • Avoid scams by acting locally or paying with PayPal
  • Never pay with Western Union, Moneygram or other anonymous payment services
  • Don't buy or sell outside of your country. Don't accept cashier cheques from outside your country
  • This site is never involved in any transaction, and does not handle payments, shipping, guarantee transactions, provide escrow services, or offer "buyer protection" or "seller certification"

Related listings

  • Linaclotide

    Linaclotide

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    Linaclotide is a 14-amino acid peptide indicated for the treatment of adults with CC and IBS-C; agonist of guanylate cyclase C. https://www.creative-peptides.com/product/linaclotide-item-10-101-161-33647.html

  • Ecallantide

    Ecallantide

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    HAE is caused by a mutation of the C1-inhibitor gene. Defective or missing C1-inhibitor permits activation of kallikrein, a protease that is responsible for liberating bradykinin from its precursor kininogen. An excess of bradykinin leads to fluid le...

  • Dulaglutide

    Dulaglutide

    Drug Development Shirley (New York) July 20, 2020 Check with publisher

    Dulaglutide is a novel glucagon-like peptide-1 agonist (GLP-1) biologic drug consisting of a dipeptidyl peptidase-IV-protected GLP-1 analogue covalently linked to a human IgG4-Fc heavy chain by a small peptide linker. https://www.creative-peptides.co...